PDF(1261 KB)
药品加快上市程序在儿童用药注册体系中的作用与思考
袁利佳, 王丽卿, 汪小燕, 张宁
PDF(1261 KB)
PDF(1261 KB)
药品加快上市程序在儿童用药注册体系中的作用与思考
The Role and Consideration of Accelerated Approval Process in Pediatric Drug Registration System
儿童用药 / 药品注册 / 加快程序 {{custom_keyword}} /
pediatric drug / drug regisration / accelerated system {{custom_keyword}} /
[1] 国家统计局．第七次全国人口普查公报(第五号)— 人口年龄构成情况[EB/OL]．(2021-05-11)[2022-07- 22]．http://www．stats．gov．cn/xxgk/sjfb/zxfb2020/ 202105/t20210511_1817200．html．
[2] 余明莲, 杨 悦．我国儿童用药可获得性的调查分析 [J]．解放军药学学报, 2011, 27(4): 368-372．
[3] 龚传欢, 杨 悦, 田丽娟．儿科药物研发激励政策研究 [J]．中国新药杂志, 2022, 31(11): 1042-1047．
[4] 许淑红, 张 绮, 张林琦, 等．探讨我国儿童用药的发展现 状及政策层面的思考 [J]．中国临床药理学杂志, 2020, 36(12): 1760-1767．
[5] FDA．Pediatric Research Equity Act | PREA [EB/OL]． (2019-07-11)[2022-07-22]．https://www．fda．gov/ drugs/development-resources/pediatric-research-equity-actprea．
[6] FDA．Best Pharmaceuticals for Children Act (BPCA) [EB/ OL]．(2018-09-25)[2022-07-22]．https://www．fda． gov/drugs/development-resources/best-pharmaceuticalschildren- act-bpca．
[7] FDA．Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans [EB/OL]．(2020-08-03)[2022-07- 22]．https://www．fda．gov/regulatory-information/ search-fda-guidance-documents/pediatric-study-planscontent- and-process-submitting-initial-pediatric-study-plansand- amended．
[8] FDA．Pediatric labeling changes [EB/OL]．(2022-08-30) [2022-09-01]．https://www．fda．gov/science-research/ pediatrics/pediatric-labeling-changes．
[9] FDA．Food and Drug Administration Moderization Act of 1997[EB/OL]．(1997-11-21)[2022-07-22]．https:// w w w．congress．gov/105/p l a w s/publ115/PLAW- 105publ115．pdf．
[10] FDA．List of drugs for which pediatric studies are needed [EB/OL]．(2019-04-29)[2022-07-22]．h t t p s :/ / cacmap．fda．gov/drugs/development-resources/listdrugs- which-pediatric-studies-are-needed．
[11] FDA．Office of pediatric therapeutics [EB/OL]．(2021- 10-25)[2022-07-22]．https://www．fda．gov/aboutfda/ office-clinical-policy-and-programs/office-pediatrictherapeutics．
[12] FDA．Pediatric Advisory Committee [EB/OL]．(2022- 04-13)[2022-07-22]．https://www．fda．gov/advisorycommittees/ committees-and-meeting-materials/pediatricadvisory- committee．
[13] FDA．Pediatric Review Committee (PeRC) [EB/OL]． (2018-06-15)[2022-07-22]．https://www．fda．gov/ drugs/development-resources/pediatric-review-committeeperc．
[14] FDA．Expedited programs for serious conditions––drugs and biologics [EB/OL]．(2020-06-25)[2022-07-22]． https://www．fda．gov/regulatory-information/searchfda- guidance-documents/expedited-programs-seriousconditions- drugs-and-biologics． [15] 岳志华, 李慧义．中美两国儿童用药安全性监测对比研究 [J]．中国医药工业杂志, 2017, 48(6): 925-929．
[16] EMA．Paediatric investigation plans [EB/OL]．[2022- 07-22]．https://www．ema．europa．eu/en/humanregulatory/ research-development/paediatric-medicines/ paediatric-investigation-plans．
[17] EMA．Better medicines for children [EB/OL]．[2022- 07-22]．https://www．ema．europa．eu/en/documents/ leaflet/better-medicines-children_en．pdf．
[18] EMA．Paediatric Committee(PDCO)[EB/OL]．[2022- 07-22]．https://www．ema．europa．eu/en/committees/ paediatric-committee-pdco#:～:text=The％20Paediatric ％20Commi t tee％20％28PDCO％29％20is％20the％ 20European％20Medicines,by％20providing％20scientific％ 20expertise％20and％20defining％20paediatric％20needs ．
[19] EMA．Needs for Paediatric Medicines [EB/OL]．[2022- 07-22]．https://www．ema．europa．eu/en/humanregulatory/ research-development/paediatric-medicines/ needs-paediatric-medicines．
[20] EMA．European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics [EB/OL]．[2022-07-22]．https://www． ema．europa．eu/en/documents/report/europeanmedicines- agency-european-commission-dg-health-foodsafety- action-plan-paediatrics_en．pdf．
[21] EMA．Conduct of pharmacovigilance for medicines used by the paediatric population [EB/OL]．[2022-07- 22]．https://www．ema．europa．eu/en/conductpharmacovigilance- medicines-used-paediatric-population．
[22] BLAKE K V, SAINT-RAYMOND A, ZACCARIA C, et al．Enhanced paediatric pharmacovigilance at the european medicines agency: a novel query applied to adverse drug reaction reports [J]．Pediatric Drugs, 2016, 18(1): 55-63．
[23] 丁锦希, 任宏业, 蒋 蓉．日本临床急需儿童药品政策法 规及启示研究[J]．现代商贸工业, 2016, (13): 125-126．
[24] 日本厚生劳动省．药事管理法[EB/OL]．(2013-06-14)[2022-07-22]．http://roppou．mark-point．jp/条文/薬事 法．html． [25] PMDA．Enforcement of the ministerial ordinance to partially revise the ministerial ordinance on the criteria for post-marketing surveillance of pharmaceutical products and review of post-marketing surveillance related to reexamination of pharmaceutical products [EB/OL]． [2022-07-22]．https://www．pmda．go．jp/reviewservices/ inspections/reexam-reeval/0004．html．
[26] 陈 薇, 欧阳昭连, 郭文姣, 等．日本儿童用药监管策略研 究[J]．中国药学杂志, 2014, 49(7): 618-621．
[27] 国家卫生计生委, 国家发展改革委, 工业和信息化部, 等． 关于保障儿童用药的若干意见[EB/OL]．(2014-05-30) [2022-07-22]．http://www．nhc．gov．cn/cms-search/ xxgk/getManuscriptXxgk．htm?id=e51354d631944fa68aac 0c4d9585f291．
[28] 佚名．全国药品注册管理和药品上市后监管工作会议 [EB/OL]．(2022-01-27)[2022-07-22]．https://www． nmpa．gov．cn/yaowen/ypjgyw/hyxx/20220127092222164． html．
[29] 佚名．“组合拳”助解儿童用药难题[EB/OL]．(2022- 06-15)[2022-07-22]．https://www．cde．org．cn/main/ news/viewInfoCommon/701873e3d25e34d2a460b03a1 2f90899．
[30] 国家药品监督管理局． 2 0 2 1 年度药品审评报告 [EB/OL]．(2022-06-01)[2022-07-22]．h t t p s :/ / w w w．nmpa．gov．cn/xxgk/f g w j/g z w j/g z w j y p/ 20220601110541120．html．
/
| 〈 |
|
〉 |
